Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06986785) titled 'A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Condition:
Advanced Hepatocellular Carcinoma
Intervention:
Drug: BL-B01D1
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 2025
Target Sample Size: 46
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06986785
Di...